These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32729019)

  • 1. Marketing of Tenofovir Disoproxil Fumarate (TDF) Lawsuits and Social Media Misinformation Campaigns' Impact on PrEP Uptake Among Gender and Sexual Minority Individuals.
    Grov C; Westmoreland DA; D'Angelo AB; Johnson J; Nash D; Daskalakis DC;
    AIDS Behav; 2021 May; 25(5):1396-1404. PubMed ID: 32729019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C
    AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G; Sauermilch D; Gandhi M; Starks TJ
    AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
    Liegeon G; Antoni G; Pialoux G; Capitant C; Cotte L; Charreau I; Tremblay C; Cua E; Senneville E; Raffi F; Meyer L; Molina JM;
    J Int AIDS Soc; 2020 Feb; 23(2):e25420. PubMed ID: 32086878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
    Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
    J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Spencer H; Bougatsos C; Blazina I; Ahmed A; Selph S
    JAMA; 2023 Aug; 330(8):746-763. PubMed ID: 37606667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.
    Petruccelli KCS; Baía-da-Silva DC; Val F; Valões MS; Cubas-Vega N; Silva-Neto AV; Sampaio V; Alencar A; Pecoits-Filho R; Moreira RC; Cardoso SW; Moreira RI; Leite IC; Madruga JV; Kallas EG; Alencastro PR; Hoagland B; Grinsztejn B; Santos VGV; Lacerda MVG
    AIDS Res Ther; 2022 Feb; 19(1):12. PubMed ID: 35209929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis.
    Van Slyke L; Scott M
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218760846. PubMed ID: 29534653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen.
    Mujugira A; Baeten JM; Hodges-Mameletzis I; Haberer JE
    Drugs; 2020 Dec; 80(18):1881-1888. PubMed ID: 33040323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy.
    Godinez H; Xu Q; McMann TJ; Li J; Mackey TK
    Front Public Health; 2023; 11():1073813. PubMed ID: 37457283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.
    McManus KA; Fuller B; Killelea A; Strumpf A; Powers SD; Rogawski McQuade ET
    JAMA Netw Open; 2023 Nov; 6(11):e2342781. PubMed ID: 37948076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
    Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
    JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and Opportunities for Preexposure Prophylaxis.
    Cambou MC; Landovitz RJ
    Top Antivir Med; 2021; 29(4):399-406. PubMed ID: 34856093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Kiarie J; Ronald A; Baeten JM;
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):374-80. PubMed ID: 26914909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review.
    Fields SD; Tung E
    Infect Dis Ther; 2021 Mar; 10(1):165-186. PubMed ID: 33569743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.